Imagine trying to find the perfect key for a lock, but you have to forge thousands of keys by hand to see which one fits. This technology uses a computer to simulate the fit first, predicting exactly which 'key' (phage) will unlock and destroy a specific 'lock' (bacteria). It's like using a digital twin of a virus to skip the slow trial-and-error process in a lab.
Matching therapeutic phages to bacterial strains currently takes years of manual laboratory work. This slow process delays the delivery of life-saving personalized therapies to patients.
An AI-driven in-silico platform capable of predicting phage effectiveness, suggesting potency-increasing mutations, and providing explanations for these predictions.
If you are a phage therapy developer dealing with years of calibration for therapy recipes — this project developed an AI platform that predicts phage effectiveness and suggests mutations to increase potency. This reduces the need for 90 out of 100 physical experiments.
If you are a probiotic manufacturer dealing with complex microbiome modulation — this project developed a prediction engine for microbial data. It allows for the design of modern probiotics based on simulated biological interactions.
If you are a personalized medicine clinic dealing with slow turnaround times for patient-specific treatments — this project developed an in-silico simulation tool. It enables the dynamic generation of personalized therapies for specific patients.
Based on available project data, specific pricing or cost structures for the platform are not provided.
The project aims to replace 90% of wet-lab experiments with in-silico simulations, which suggests a significant capacity for industrial scaling in drug discovery.
Based on available project data, the technology is being developed by Camino Science Sp. z o.o., but specific licensing terms are not mentioned.
The tool is designed to strengthen the capabilities of research groups by acting as an AI assistant that reduces the number of required in vitro experiments.
The project period is from 2023-01-01 to 2025-05-31, indicating the development phase is currently active.
The project is led by a single Polish SME, Camino Science Sp. z o.o., with a 100% industry ratio. This lean structure suggests a highly focused commercial drive, though it lacks academic or large-scale industrial partners within the formal consortium.
Contact Camino Science Sp. z o.o. in Poland
Contact us to explore licensing opportunities for this AI-driven phage prediction engine.
